Neutral
Johnson & Johnson's stock drops 1.6% amid analyst target hikes and pipeline updates
Despite recent analyst target increases and positive pipeline developments, Johnson & Johnson's stock declined by 1.6% to approximately $267.66. This movement reflects investor caution amid ongoing concerns over near-term earnings and valuation.
Key points
- Bank of America raised its price target for JNJ to $278 from $263, citing improved outlook for the psoriasis drug Icotyde.
- JPMorgan also increased its price target to $285 from $270, maintaining a Neutral rating, indicating potential upside based on the new target.
- Recent pipeline updates, including positive data for IMAAVY, Tremfya, and Caplyta, strengthen the company's growth prospects post-Stelara.
- Despite these positive developments, the stock's valuation near 31 times earnings and concerns over ongoing litigation costs contribute to investor caution.
Sources
AI-generated from public news sources. Not financial advice.
